Overexpression of EGFR plays a key role in HNSCC, supporting the use of cetuximab, a monoclonal anti‐EGFR antibody, as well as EGFR‐tyrosine kinase inhibitors (EGFR‐TKI), which inhibit tumor cell proliferation and the secretion of pro‐angiogenic factors by tumor cells, such as VEGF and IL‐8. This evidence concerns the gene EGFR and head and neck squamous cell carcinoma.